DK0941227T5 - Epothilon D, dens fremstilling samt dens anvendelse som cytostatisk middel og som plantebeskyttelsesmiddel - Google Patents

Epothilon D, dens fremstilling samt dens anvendelse som cytostatisk middel og som plantebeskyttelsesmiddel

Info

Publication number: DK0941227T5
Authority: DK; Denmark
Prior art keywords: epothilone; agent; methanol; preparation; plant protection
Prior art date: 1996-11-18

Application number

DK97951233T

Other languages

English (en)

Other versions

DK0941227T4 (da

DK0941227T3 (da

Inventor

Hans Reichenbach

Gerhard Hoefle

Klaus Gerth

Heinrich Steinmetz

Original Assignee

Biotechnolog Forschung Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-11-18

Filing date

1997-11-18

Publication date

2009-10-05

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26031383&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0941227(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1997-11-18 Application filed by Biotechnolog Forschung Gmbh filed Critical Biotechnolog Forschung Gmbh

2004-06-28 Application granted granted Critical

2004-06-28 Publication of DK0941227T3 publication Critical patent/DK0941227T3/da

2008-05-19 Publication of DK0941227T4 publication Critical patent/DK0941227T4/da

2009-10-05 Publication of DK0941227T5 publication Critical patent/DK0941227T5/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/72—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms
- A01N43/74—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,3
- A01N43/78—1,3-Thiazoles; Hydrogenated 1,3-thiazoles
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
- A01N63/20—Bacteria; Substances produced thereby or obtained therefrom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
- C12P17/167—Heterorings having sulfur atoms as ring heteroatoms, e.g. vitamin B1, thiamine nucleus and open chain analogs
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
- C12P17/181—Heterocyclic compounds containing oxygen atoms as the only ring heteroatoms in the condensed system, e.g. Salinomycin, Septamycin

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
General Health & Medical Sciences (AREA)
Wood Science & Technology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Dentistry (AREA)
Pest Control & Pesticides (AREA)
Agronomy & Crop Science (AREA)
Plant Pathology (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Environmental Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Genetics & Genomics (AREA)
General Engineering & Computer Science (AREA)
Biochemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicinal Chemistry (AREA)
Virology (AREA)
Oncology (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Silicon Polymers (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Epoxy Compounds (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Steroid Compounds (AREA)

DK97951233T 1996-11-18 1997-11-18 Epothilon D, dens fremstilling samt dens anvendelse som cytostatisk middel og som plantebeskyttelsesmiddel DK0941227T5 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DE19647580		1996-11-18
DE19707506		1997-02-25
PCT/EP1997/006442 WO1998022461A1 (de)	1996-11-18	1997-11-18	Epothilone c, d, e und f, deren herstellung und deren verwendung als cytostatische mittel bzw. als pflanzenschutzmittel

Publications (3)

Publication Number	Publication Date
DK0941227T3 DK0941227T3 (da)	2004-06-28
DK0941227T4 DK0941227T4 (da)	2008-05-19
DK0941227T5 true DK0941227T5 (da)	2009-10-05

Family

ID=26031383

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK97951233T DK0941227T5 (da)	1996-11-18	1997-11-18	Epothilon D, dens fremstilling samt dens anvendelse som cytostatisk middel og som plantebeskyttelsesmiddel
DK03016552T DK1367057T3 (da)	1996-11-18	1997-11-18	Epothiloner E og F

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK03016552T DK1367057T3 (da)	1996-11-18	1997-11-18	Epothiloner E og F

Country Status (24)

Country	Link
US (6)	US7067544B2 (da)
EP (2)	EP0941227B2 (da)
JP (1)	JP4274583B2 (da)
KR (1)	KR100538095B1 (da)
CN (2)	CN1196698C (da)
AT (2)	ATE408612T1 (da)
AU (1)	AU753546B2 (da)
BR (1)	BR9713363B1 (da)
CA (1)	CA2269118C (da)
CY (1)	CY2542B1 (da)
CZ (2)	CZ296164B6 (da)
DE (2)	DE59711647D1 (da)
DK (2)	DK0941227T5 (da)
ES (2)	ES2221692T5 (da)
HK (2)	HK1022314A1 (da)
HU (1)	HU229833B1 (da)
IL (1)	IL129558A (da)
NO (1)	NO319984B1 (da)
NZ (1)	NZ335383A (da)
PL (1)	PL193229B1 (da)
PT (2)	PT941227E (da)
RU (1)	RU2198173C2 (da)
TW (1)	TW408119B (da)
WO (1)	WO1998022461A1 (da)

Families Citing this family (176)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT1186606E (pt)	1995-11-17	2004-08-31	Biotechnolog Forschung Mbh Gbf	Derivados do epotilone sua preparacao e utilizacao
US5969145A (en) *	1996-08-30	1999-10-19	Novartis Ag	Process for the production of epothilones and intermediate products within the process
AU753546B2 (en)	1996-11-18	2002-10-24	Helmholtz-Zentrum Fuer Infektionsforschung Gmbh	Epothilone C, D, E and F, production process, and their use as cytostatic as well as phytosanitary agents
EP0977563B1 (en) *	1996-12-03	2005-10-12	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6867305B2 (en)	1996-12-03	2005-03-15	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
US6204388B1 (en)	1996-12-03	2001-03-20	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
US6441186B1 (en) *	1996-12-13	2002-08-27	The Scripps Research Institute	Epothilone analogs
US6380394B1 (en)	1996-12-13	2002-04-30	The Scripps Research Institute	Epothilone analogs
US6660758B1 (en)	1996-12-13	2003-12-09	The Scripps Research Institute	Epothilone analogs
US6605599B1 (en)	1997-07-08	2003-08-12	Bristol-Myers Squibb Company	Epothilone derivatives
US6320045B1 (en)	1997-12-04	2001-11-20	Bristol-Myers Squibb Company	Process for the reduction of oxiranyl epothilones to olefinic epothilones
US6365749B1 (en)	1997-12-04	2002-04-02	Bristol-Myers Squibb Company	Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
US6683100B2 (en)	1999-01-19	2004-01-27	Novartis Ag	Organic compounds
US6194181B1 (en)	1998-02-19	2001-02-27	Novartis Ag	Fermentative preparation process for and crystal forms of cytostatics
FR2775187B1 (fr)	1998-02-25	2003-02-21	Novartis Ag	Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6380395B1 (en)	1998-04-21	2002-04-30	Bristol-Myers Squibb Company	12, 13-cyclopropane epothilone derivatives
US6498257B1 (en) *	1998-04-21	2002-12-24	Bristol-Myers Squibb Company	2,3-olefinic epothilone derivatives
DE19820599A1 (de)	1998-05-08	1999-11-11	Biotechnolog Forschung Gmbh	Epothilonderivate, Verfahren zu deren Herstellung und deren Verwendung
DE19826988A1 (de) *	1998-06-18	1999-12-23	Biotechnolog Forschung Gmbh	Epothilon-Nebenkomponenten
NZ508326A (en) *	1998-06-18	2003-10-31	Novartis Ag	A polyketide synthase and non ribosomal peptide synthase genes, isolated from a myxobacterium, necessary for synthesis of epothiones A and B
DE19846493A1 (de) *	1998-10-09	2000-04-13	Biotechnolog Forschung Gmbh	DNA-Sequenzen für die enzymatische Synthese von Polyketid- oder Heteropolyketidverbindungen
US6410301B1 (en)	1998-11-20	2002-06-25	Kosan Biosciences, Inc.	Myxococcus host cells for the production of epothilones
KR100716272B1 (ko)	1998-11-20	2007-05-09	코산 바이오사이언시즈, 인코포레이티드	에포틸론 및 에포틸론 유도체의 생산을 위한 재조합 방법 및 물질
US6780620B1 (en)	1998-12-23	2004-08-24	Bristol-Myers Squibb Company	Microbial transformation method for the preparation of an epothilone
CA2356360A1 (en) *	1998-12-23	2000-07-06	Bristol-Myers Squibb Company	Microbial transformation method for the preparation of an epothilone
US6596875B2 (en)	2000-02-07	2003-07-22	James David White	Method for synthesizing epothilones and epothilone analogs
CN1205208C (zh) *	1999-02-22	2005-06-08	生物技术研究股份有限公司	C－21修饰的环氧噻酮类化合物
US6291684B1 (en)	1999-03-29	2001-09-18	Bristol-Myers Squibb Company	Process for the preparation of aziridinyl epothilones from oxiranyl epothilones
US7125875B2 (en)	1999-04-15	2006-10-24	Bristol-Myers Squibb Company	Cyclic protein tyrosine kinase inhibitors
KR100722344B1 (ko)	1999-04-15	2007-05-29	브리스톨-마이어스스퀴브컴파니	환형 단백질 티로신 키나제 억제제
EP1229934B1 (en)	1999-10-01	2014-03-05	Immunogen, Inc.	Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US6518421B1 (en) *	2000-03-20	2003-02-11	Bristol-Myers Squibb Company	Process for the preparation of epothilone analogs
US6593115B2 (en)	2000-03-24	2003-07-15	Bristol-Myers Squibb Co.	Preparation of epothilone intermediates
US6998256B2 (en)	2000-04-28	2006-02-14	Kosan Biosciences, Inc.	Methods of obtaining epothilone D using crystallization and /or by the culture of cells in the presence of methyl oleate
US6589968B2 (en)	2001-02-13	2003-07-08	Kosan Biosciences, Inc.	Epothilone compounds and methods for making and using the same
ES2254493T3 (es) *	2000-04-28	2006-06-16	Kosan Biosciences, Inc.	Produccion heterologa de policetidos.
UA75365C2 (en) *	2000-08-16	2006-04-17	Bristol Myers Squibb Co	Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
GB0029895D0 (en) *	2000-12-07	2001-01-24	Novartis Ag	Organic compounds
CA2434566A1 (en)	2001-01-25	2002-08-15	Timothy M. Malloy	Parenteral formulation containing epothilone analogs
HU229349B1 (en)	2001-01-25	2013-11-28	Bristol Myers Squibb Co	Methods for preparation of pharmaceutical composition containing epothilone analogs useful for treatment of cancer
WO2002058699A1 (en) *	2001-01-25	2002-08-01	Bristol-Myers Squibb Company	Pharmaceutical forms of epothilones for oral administration
US6893859B2 (en)	2001-02-13	2005-05-17	Kosan Biosciences, Inc.	Epothilone derivatives and methods for making and using the same
KR20040028720A (ko)	2001-02-20	2004-04-03	브리스톨-마이어스스퀴브컴파니	치료불응성 종양 치료용 에포틸론 유도체
IL156988A0 (en)	2001-02-20	2004-02-08	Bristol Myers Squibb Co	Pharmaceutical compositions containing epothilone derivatives
EP1364040B1 (en)	2001-02-27	2006-05-03	Gesellschaft für biotechnologische Forschung mbH (GBF)	Degradation of epothilones and ethynyl substituted epothilones
SK287489B6 (sk)	2001-02-27	2010-11-08	Novartis Ag	Kombinácia inhibítora PDGF receptorovej tyrozínkinázy a derivátu epotilónu, farmaceutická kompozícia s jej obsahom a jej použitie
KR20040025904A (ko)	2001-03-14	2004-03-26	브리스톨-마이어스 스큅 컴퍼니	증식성 질환의 치료를 위한 에포틸론 유사체 및화학치료제의 병용
MXPA03010909A (es)	2001-06-01	2004-02-17	Bristol Myers Squibb Co	Derivados de epotilona.
TWI315982B (en)	2001-07-19	2009-10-21	Novartis Ag	Combinations comprising epothilones and pharmaceutical uses thereof
TWI287986B (en) *	2001-12-13	2007-10-11	Novartis Ag	Use of Epothilones for the treatment of the carcinoid syndrome
US6884608B2 (en)	2001-12-26	2005-04-26	Bristol-Myers Squibb Company	Compositions and methods for hydroxylating epothilones
TWI341728B (en)	2002-01-14	2011-05-11	Novartis Ag	Combinations comprising epothilones and anti-metabolites
TW200303202A (en)	2002-02-15	2003-09-01	Bristol Myers Squibb Co	Method of preparation of 21-amino epothilone derivatives
DE60330651D1 (en)	2002-03-12	2010-02-04	Bristol Myers Squibb Co	C3-cyanoepothilonderivate
AU2003218107A1 (en)	2002-03-12	2003-09-29	Bristol-Myers Squibb Company	C12-cyano epothilone derivatives
TW200403994A (en)	2002-04-04	2004-03-16	Bristol Myers Squibb Co	Oral administration of EPOTHILONES
TW200400191A (en)	2002-05-15	2004-01-01	Bristol Myers Squibb Co	Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
US7405234B2 (en)	2002-05-17	2008-07-29	Bristol-Myers Squibb Company	Bicyclic modulators of androgen receptor function
WO2003105828A1 (en)	2002-06-14	2003-12-24	Bristol-Myers Squibb Company	Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
AU2003251902B2 (en) *	2002-07-29	2008-03-06	Merck Sharp & Dohme Llc	Tiacumicin production
ATE450534T1 (de) *	2002-08-23	2009-12-15	Sloan Kettering Inst Cancer	Synthese von epothilonen, zwischenprodukte davon, analoga und ihre verwendung
RU2368661C2 (ru)	2002-09-23	2009-09-27	Бристол-Маерс Сквибб Компани	Способы получения, выделения и очистки эпотилона b и рентгеноструктурные кристаллические структуры эпотилона в
PT1553938E (pt) *	2002-10-15	2007-03-30	Univ Louisiana State	Utilização de derivados de epotilona para o tratamento do hiperparatiroidismo
EP1567487A4 (en)	2002-11-15	2005-11-16	Bristol Myers Squibb Co	OPEN-CHAINED, PROLYL-FROSTED MODULATORS OF ANDROGEN RECEPTOR FUNCTION
CN100359014C (zh) *	2003-01-28	2008-01-02	北京华昊中天生物技术有限公司	一类新型埃坡霉素化合物及其制备方法和用途
US20050171167A1 (en)	2003-11-04	2005-08-04	Haby Thomas A.	Process and formulation containing epothilones and analogs thereof
EP1559447A1 (en)	2004-01-30	2005-08-03	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism
US7820702B2 (en)	2004-02-04	2010-10-26	Bristol-Myers Squibb Company	Sulfonylpyrrolidine modulators of androgen receptor function and method
US7378426B2 (en)	2004-03-01	2008-05-27	Bristol-Myers Squibb Company	Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US7696241B2 (en)	2004-03-04	2010-04-13	Bristol-Myers Squibb Company	Bicyclic compounds as modulators of androgen receptor function and method
US7625923B2 (en)	2004-03-04	2009-12-01	Bristol-Myers Squibb Company	Bicyclic modulators of androgen receptor function
ES2396195T3 (es)	2004-04-07	2013-02-19	Novartis Ag	Inhibidores de IAP
US10675326B2 (en)	2004-10-07	2020-06-09	The Board Of Trustees Of The University Of Illinois	Compositions comprising cupredoxins for treating cancer
BRPI0518286A2 (pt) *	2004-11-18	2008-11-11	Bristol Myers Squibb Co	microesfera com revestimento entÉrico contendo ixabepilona e sua preparaÇço
EP1824458A1 (en) *	2004-11-18	2007-08-29	Bristol-Myers Squibb Company	Enteric coated bead comprising epothilone or an epothilone analog, and preparation and administration thereof
US20060121511A1 (en)	2004-11-30	2006-06-08	Hyerim Lee	Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
GB0510390D0 (en)	2005-05-20	2005-06-29	Novartis Ag	Organic compounds
US20080255149A1 (en)	2005-09-27	2008-10-16	Novartis Ag	Carboxyamine Compounds and Methods of Use Thereof
NO20220050A1 (no)	2005-11-21	2008-08-12	Novartis Ag	Neuroendokrin tumorbehandling
GB0605120D0 (en)	2006-03-14	2006-04-26	Novartis Ag	Organic Compounds
CA2647565A1 (en)	2006-03-31	2007-10-18	Bristol-Myers Squibb Company	Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
WO2007115289A2 (en)	2006-04-05	2007-10-11	Novartis Ag	Combinations comprising bcr-abl/c-kit/pdgf-r tk inhibitors for treating cancer
KR20080108517A (ko)	2006-04-05	2008-12-15	노파르티스 아게	암을 치료하기 위한 치료제의 조합물
KR20090007635A (ko)	2006-05-09	2009-01-19	노파르티스 아게	철 킬레이터 및 항-신생물 약제를 포함하는 조합물 및 그의용도
RU2009115954A (ru)	2006-09-29	2010-11-10	Новартис АГ (CH)	Пиразолопиримидины в качестве ингибиторов липидной киназы р13к
JP2010511408A (ja)	2006-12-04	2010-04-15	ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ	癌をＣｐＧリッチＤＮＡおよびキュプレドキシンで治療するための組成物および方法
JP2010518123A (ja)	2007-02-08	2010-05-27	ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ	癌をキュプレドキシンで予防するための組成物および方法
AR065335A1 (es)	2007-02-15	2009-06-03	Novartis Ag	Combinaciones de agentes terapeuticos para el tratamiento de cancer
AU2009228765B2 (en)	2008-03-24	2012-05-31	Novartis Ag	Arylsulfonamide-based matrix metalloprotease inhibitors
CA2719477C (en)	2008-03-26	2016-11-08	Novartis Ag	Hydroxamate-based inhibitors of deacetylases b
CN101362784A (zh) *	2008-10-06	2009-02-11	山东大学	埃博霉素苷类化合物和以其为活性成分的组合物及其应用
WO2010083617A1 (en)	2009-01-21	2010-07-29	Oncalis Ag	Pyrazolopyrimidines as protein kinase inhibitors
TW201031406A (en)	2009-01-29	2010-09-01	Novartis Ag	Substituted benzimidazoles for the treatment of astrocytomas
ES2475945T3 (es)	2009-06-26	2014-07-11	Novartis Ag	Derivados imidazolidin-2 -ona 1,3-disustituida como inhibidores de CYP 17
US8389526B2 (en)	2009-08-07	2013-03-05	Novartis Ag	3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
CA2770873A1 (en)	2009-08-12	2011-02-17	Novartis Ag	Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
KR20120089463A (ko)	2009-08-20	2012-08-10	노파르티스 아게	헤테로시클릭 옥심 화합물
US20120149661A1 (en)	2009-08-26	2012-06-14	Novartis Ag	Tetra-substituted heteroaryl compounds and their use as mdm2 and/or mdm4 modulators
PE20121471A1 (es)	2009-11-04	2012-11-01	Novartis Ag	Derivados de sulfonamida heterociclicos utiles como inhibidores de mek
WO2011070030A1 (en)	2009-12-08	2011-06-16	Novartis Ag	Heterocyclic sulfonamide derivatives
CU24130B1 (es)	2009-12-22	2015-09-29	Novartis Ag	Isoquinolinonas y quinazolinonas sustituidas
US8440693B2 (en)	2009-12-22	2013-05-14	Novartis Ag	Substituted isoquinolinones and quinazolinones
CA2927832C (en)	2010-05-18	2021-03-23	Cerulean Pharma Inc.	Cyclodextrin-containing polymer-therapeutic agent conjugates and their use
UA112517C2 (uk)	2010-07-06	2016-09-26	Новартіс Аг	Тетрагідропіридопіримідинові похідні
JP2013537210A (ja)	2010-09-16	2013-09-30	ノバルティスアーゲー	１７α−ヒドロキシラーゼ／Ｃ１７，２０−リアーゼ阻害剤
JP5889337B2 (ja)	2011-01-20	2016-03-22	ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム	Ｍｒｉマーカー、送達および抜取りシステムならびにこれらの製造方法および使用方法
JP2014505088A (ja)	2011-02-10	2014-02-27	ノバルティスアーゲー	Ｃ−ＭＥＴチロシンキナーゼ阻害剤としての［１，２，４］トリアゾロ［４，３−ｂ］ピリダジン化合物
JP6002210B2 (ja)	2011-04-28	2016-10-05	ノバルティスアーゲー	１７α−ヒドロキシラーゼ／Ｃ１７，２０−リアーゼ阻害剤
CA2838029A1 (en)	2011-06-09	2012-12-13	Novartis Ag	Heterocyclic sulfonamide derivatives
RU2617402C2 (ru)	2011-06-10	2017-04-25	Мерсана Терапьютикс, Инк.	Конъюгаты белок-полимер-лекарственное средство
EP2721007B1 (en)	2011-06-20	2015-04-29	Novartis AG	Cyclohexyl isoquinolinone compounds
EP2721008B1 (en)	2011-06-20	2015-04-29	Novartis AG	Hydroxy substituted isoquinolinone derivatives as p53 (mdm2 or mdm4) inhibitors
EP2723740A1 (en)	2011-06-27	2014-04-30	Novartis AG	Solid forms and salts of tetrahydro-pyrido-pyrimidine derivatives
CN102863474A (zh)	2011-07-09	2013-01-09	陈小平	一类治疗细胞增殖性疾病的铂化合物、其制备方法和应用
CA2848809A1 (en)	2011-09-15	2013-03-21	Novartis Ag	6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyradines as c-met tyrosine kinase
CN102993239A (zh)	2011-09-19	2013-03-27	陈小平	离去基团含氨基或烷胺基的丁二酸衍生物的铂类化合物
JP5992054B2 (ja)	2011-11-29	2016-09-14	ノバルティスアーゲー	ピラゾロピロリジン化合物
WO2013093850A1 (en)	2011-12-22	2013-06-27	Novartis Ag	Quinoline derivatives
JP5903499B2 (ja)	2011-12-22	2016-04-13	ノバルティスアーゲー	ジヒドロ−ベンゾ−オキサジンおよびジヒドロ−ピリド−オキサジン誘導体
WO2013096059A1 (en)	2011-12-23	2013-06-27	Novartis Ag	Compounds for inhibiting the interaction of bcl2 with binding partners
KR20140107578A (ko)	2011-12-23	2014-09-04	노파르티스 아게	Bcl2와 결합 파트너의 상호작용을 억제하기 위한 화합물
US20140357666A1 (en)	2011-12-23	2014-12-04	Novartis Ag	Compounds for inhibiting the interaction of bcl2 with binding partners
MX2014007729A (es)	2011-12-23	2015-01-12	Novartis Ag	Compuestos para inhibir la interaccion de bcl2 con los componentes de enlace.
BR112014015339A8 (pt)	2011-12-23	2017-06-13	Novartis Ag	compostos para inibição da interação de bcl2 com parceiros de ligação
KR101372563B1 (ko)	2011-12-26	2014-03-14	주식회사 삼양바이오팜	에포틸론 함유물질로부터 에포틸론 ａ와 ｂ의 추출 및 정제 방법
UY34591A (es)	2012-01-26	2013-09-02	Novartis Ag	Compuestos de imidazopirrolidinona
MX2014013373A (es)	2012-05-15	2015-08-14	Novartis Ag	Derivados de benzamida para inhibir la actividad de abl1, abl2 y bcr-abl1.
PT2861579T (pt)	2012-05-15	2018-04-27	Novartis Ag	Derivados de benzamida para inibir a atividade de abl1, abl2 e bcr-abl
BR112014027584B1 (pt)	2012-05-15	2023-01-24	Novartis Ag	Uso de inibidores da atividade de abl1, abl2 e bcr-abl1, e composição farmacêutica
JP6204975B2 (ja)	2012-05-15	2017-09-27	ノバルティスアーゲー	Ａｂｌ１、ａｂｌ２およびｂｃｒ−ａｂｌ１の活性を阻害するためのベンズアミド誘導体
CN104321325B (zh)	2012-05-24	2016-11-16	诺华股份有限公司	吡咯并吡咯烷酮化合物
EP2861256B1 (en)	2012-06-15	2019-10-23	The Brigham and Women's Hospital, Inc.	Compositions for treating cancer and methods for making the same
CN107434803B (zh)	2012-10-02	2020-05-05	吉利德科学公司	组蛋白去甲基化酶抑制剂
WO2014075391A1 (zh)	2012-11-17	2014-05-22	北京市丰硕维康技术开发有限责任公司	离去基团是含氨基或烷氨基的丙二酸衍生物的铂类化合物
TW201422625A (zh)	2012-11-26	2014-06-16	Novartis Ag	二氫－吡啶并－□衍生物之固體形式
EP2928504B1 (en)	2012-12-10	2019-02-20	Mersana Therapeutics, Inc.	Protein-polymer-drug conjugates
EP2931316B1 (en)	2012-12-12	2019-02-20	Mersana Therapeutics, Inc.	Hydroxyl-polymer-drug-protein conjugates
JO3464B1 (ar)	2013-01-15	2020-07-05	Astellas Pharma Europe Ltd	التركيبات الخاصة بمركبات التياكوميسين
US9403827B2 (en)	2013-01-22	2016-08-02	Novartis Ag	Substituted purinone compounds
WO2014115080A1 (en)	2013-01-22	2014-07-31	Novartis Ag	Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
WO2014128612A1 (en)	2013-02-20	2014-08-28	Novartis Ag	Quinazolin-4-one derivatives
KR102229992B1 (ko)	2013-02-27	2021-03-19	에피테라퓨틱스 에이피에스	히스톤 데메틸라아제의 저해제
US20150018376A1 (en)	2013-05-17	2015-01-15	Novartis Ag	Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
WO2014198645A1 (en)	2013-06-11	2014-12-18	Bayer Pharma Aktiengesellschaft	Combinations for the treatment of cancer comprising a mps-1 kinase inhibitor and a mitotic inhibitor
UY35675A (es)	2013-07-24	2015-02-27	Novartis Ag	Derivados sustituidos de quinazolin-4-ona
WO2015022664A1 (en)	2013-08-14	2015-02-19	Novartis Ag	Compounds and compositions as inhibitors of mek
WO2015022663A1 (en)	2013-08-14	2015-02-19	Novartis Ag	Compounds and compositions as inhibitors of mek
US9227969B2 (en)	2013-08-14	2016-01-05	Novartis Ag	Compounds and compositions as inhibitors of MEK
US9670194B2 (en)	2013-09-22	2017-06-06	Calitor Sciences, Llc	Substituted aminopyrimidine compounds and methods of use
CA2926586C (en)	2013-10-11	2020-04-07	Mersana Therapeutics, Inc.	Polymeric scaffold based on phf for targeted drug delivery
US10316080B2 (en)	2013-10-11	2019-06-11	Asana Biosciences, Llc	Protein-polymer-drug conjugates
EP3122728A4 (en)	2014-03-28	2017-10-25	Calitor Sciences, LLC	Substituted heteroaryl compounds and methods of use
JP2017512804A (ja)	2014-03-31	2017-05-25	ギリアードサイエンシーズ，インコーポレイテッド	ヒストン脱メチル化酵素の阻害剤
MX2016012893A (es)	2014-04-03	2017-05-12	Invictus Oncology Pvt Ltd	Sustancias terapéuticas combinadas supramoleculares.
JP2017526675A (ja)	2014-08-27	2017-09-14	ギリアードサイエンシーズ，インコーポレイテッド	ヒストンデメチラーゼを阻害するための化合物および方法
WO2017044434A1 (en)	2015-09-11	2017-03-16	Sunshine Lake Pharma Co., Ltd.	Substituted heteroaryl compounds and methods of use
WO2018004338A1 (en)	2016-06-27	2018-01-04	Tagworks Pharmaceuticals B.V.	Cleavable tetrazine used in bio-orthogonal drug activation
US11135307B2 (en)	2016-11-23	2021-10-05	Mersana Therapeutics, Inc.	Peptide-containing linkers for antibody-drug conjugates
JP7320458B2 (ja)	2017-06-22	2023-08-03	メルサナセラピューティクスインコーポレイテッド	薬物担持ポリマースキャフォールドおよびタンパク質－ポリマー－薬物コンジュゲートを製造する方法
EP3710006A4 (en)	2017-11-19	2021-09-01	Sunshine Lake Pharma Co., Ltd.	SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR METHODS OF USE
WO2019143874A1 (en)	2018-01-20	2019-07-25	Sunshine Lake Pharma Co., Ltd.	Substituted aminopyrimidine compounds and methods of use
DK3788032T3 (da)	2018-05-04	2024-04-15	Tagworks Pharmaceuticals B V	Forbindelser omfattende en linker til øgning af transcyklooctenstabilitet
US20210299286A1 (en)	2018-05-04	2021-09-30	Tagworks Pharmaceuticals B.V.	Tetrazines for high click conjugation yield in vivo and high click release yield
WO2020092385A1 (en)	2018-10-29	2020-05-07	Mersana Therapeutics, Inc.	Cysteine engineered antibody-drug conjugates with peptide-containing linkers
FR3087650B1 (fr)	2018-10-31	2021-01-29	Bio Even	Flavine adenine dinucleotide (fad) pour son utilisation pour la prevention et/ou le traitement de cancer
EP3983363B1 (en)	2019-06-17	2024-04-10	Tagworks Pharmaceuticals B.V.	Compounds for fast and efficient click release
IL289094A (en)	2019-06-17	2022-02-01	Tagworks Pharmaceuticals B V	Tetrazines for increasing the speed and yield of the "click release" reaction
WO2023031445A2 (en)	2021-09-06	2023-03-09	Veraxa Biotech Gmbh	Novel aminoacyl-trna synthetase variants for genetic code expansion in eukaryotes
EP4186529A1 (en)	2021-11-25	2023-05-31	Veraxa Biotech GmbH	Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion
KR20240105469A (ko)	2021-11-25	2024-07-05	베락사 바이오테크 게엠베하	유전자 코드 확장을 이용하는 부위-특이적 접합에 의해 제조되는 개선된 항체-페이로드 접합체 (apc)
AU2022404647A1 (en)	2021-12-08	2024-06-13	European Molecular Biology Laboratory	Hydrophilic tetrazine-functionalized payloads for preparation of targeting conjugates
EP4314031B1 (en)	2022-02-15	2024-03-13	Tagworks Pharmaceuticals B.V.	Masked il12 protein
WO2024013723A1 (en)	2022-07-15	2024-01-18	Pheon Therapeutics Ltd	Antibody drug conjugates that bind cdcp1 and uses thereof
WO2024080872A1 (en)	2022-10-12	2024-04-18	Tagworks Pharmaceuticals B.V.	Strained bicyclononenes
WO2024153789A1 (en)	2023-01-20	2024-07-25	Basf Se	Stabilized biopolymer composition, their manufacture and use
WO2024191293A1 (en)	2023-03-10	2024-09-19	Tagworks Pharmaceuticals B.V.	Trans-cyclooctene with improved t-linker

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0358606A3 (de)	1988-09-09	1990-10-31	Gesellschaft für Biotechnologische Forschung mbH (GBF)	Mikrobiologisches Verfahren zur Herstellung agrarchemisch verwendbarer mikrobizider makrozyklischer Lactonderivate
GB8909737D0 (en)	1989-04-27	1989-06-14	Shell Int Research	Thiazole derivatives
DE4138042C2 (de) *	1991-11-19	1993-10-14	Biotechnolog Forschung Gmbh	Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
US5665767A (en)	1993-03-05	1997-09-09	Hexal Pharma Gmbh	Crystalline cyclodextrin complexes of ranitidine hydrochloride, process for their preparation and pharmaceutical compositions containing the same
WO1995018798A1 (en)	1994-01-11	1995-07-13	The Scripps Research Institute	Chemical switching of taxo-diterpenoids between low solubility active forms and high solubility inactive forms
DE19639456A1 (de)	1996-09-25	1998-03-26	Biotechnolog Forschung Gmbh	Epothilon-Derivate, Herstellung und Mittel
PT1186606E (pt)	1995-11-17	2004-08-31	Biotechnolog Forschung Mbh Gbf	Derivados do epotilone sua preparacao e utilizacao
DE19542986A1 (de) *	1995-11-17	1997-05-22	Biotechnolog Forschung Gmbh	Epothilon-Derivate und deren Verwendung
DE19645361A1 (de)	1996-08-30	1998-04-30	Ciba Geigy Ag	Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B, Teil II
DE19645362A1 (de)	1996-10-28	1998-04-30	Ciba Geigy Ag	Verfahren zur Herstellung von Epothilon A und B und Derivaten
NZ334821A (en)	1996-08-30	2000-12-22	Novartis Ag	Method for producing epothilones
DE19636343C1 (de)	1996-08-30	1997-10-23	Schering Ag	Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B
US5969145A (en) *	1996-08-30	1999-10-19	Novartis Ag	Process for the production of epothilones and intermediate products within the process
AU753546B2 (en) *	1996-11-18	2002-10-24	Helmholtz-Zentrum Fuer Infektionsforschung Gmbh	Epothilone C, D, E and F, production process, and their use as cytostatic as well as phytosanitary agents
US6515016B2 (en)	1996-12-02	2003-02-04	Angiotech Pharmaceuticals, Inc.	Composition and methods of paclitaxel for treating psoriasis
US6204388B1 (en) *	1996-12-03	2001-03-20	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
EP0977563B1 (en)	1996-12-03	2005-10-12	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6441186B1 (en)	1996-12-13	2002-08-27	The Scripps Research Institute	Epothilone analogs
US6660758B1 (en)	1996-12-13	2003-12-09	The Scripps Research Institute	Epothilone analogs
US6380394B1 (en) *	1996-12-13	2002-04-30	The Scripps Research Institute	Epothilone analogs
DE19701758A1 (de)	1997-01-20	1998-07-23	Wessjohann Ludgar A Dr	Epothilone-Synthesebausteine
CN1544436A (zh) *	1997-02-25	2004-11-10	��＼��о��޹�˾��GBF��	3，7-保护的环氧噻嗪酮-n-氧化物及其制备方法
US5828449A (en)	1997-02-26	1998-10-27	Acuity Imaging, Llc	Ring illumination reflective elements on a generally planar surface
DE19713970B4 (de)	1997-04-04	2006-08-31	R&D-Biopharmaceuticals Gmbh	Epothilone-Synthesebausteine II - Prenylderivate
EP0975622B1 (de)	1997-04-18	2002-10-09	Studiengesellschaft Kohle mbH	Selektive olefinmetathese von bi- oder polyfunktionellen substraten in komprimiertem kohlendioxid als reaktionsmedium
DE19720312A1 (de)	1997-05-15	1998-11-19	Hoechst Ag	Zubereitung mit erhöhter in vivo Verträglichkeit
DE19821954A1 (de)	1997-05-15	1998-11-19	Biotechnolog Forschung Gmbh	Verfahren zur Herstellung eines Epothilon-Derivats
DE19726627A1 (de)	1997-06-17	1998-12-24	Schering Ag	Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Epothilon
US6605599B1 (en)	1997-07-08	2003-08-12	Bristol-Myers Squibb Company	Epothilone derivatives
EP1001951B1 (de)	1997-07-16	2002-09-25	Schering Aktiengesellschaft	Thiazolderivate, verfahren zur herstellung und verwendung
ATE368036T1 (de)	1997-08-09	2007-08-15	Bayer Schering Pharma Ag	Neue epothilon-derivate, verfahren zu deren herstellung und ihre pharmazeutische verwendung
CA2320182C (en)	1998-02-05	2008-11-25	Novartis Ag	Compositions containing organic compounds
US6194181B1 (en) *	1998-02-19	2001-02-27	Novartis Ag	Fermentative preparation process for and crystal forms of cytostatics
WO1999043653A1 (en)	1998-02-25	1999-09-02	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues therof
FR2775187B1 (fr)	1998-02-25	2003-02-21	Novartis Ag	Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
DE19826988A1 (de) *	1998-06-18	1999-12-23	Biotechnolog Forschung Gmbh	Epothilon-Nebenkomponenten
WO2000000485A1 (de)	1998-06-30	2000-01-06	Schering Aktiengesellschaft	Epothilon-derivate, verfahren zu deren herstellung, zwischenprodukte und ihre pharmazeutische verwendung
US6410301B1 (en) *	1998-11-20	2002-06-25	Kosan Biosciences, Inc.	Myxococcus host cells for the production of epothilones
KR100716272B1 (ko)	1998-11-20	2007-05-09	코산 바이오사이언시즈, 인코포레이티드	에포틸론 및 에포틸론 유도체의 생산을 위한 재조합 방법 및 물질
EP1140944B1 (en)	1998-12-22	2003-08-27	Novartis AG	Epothilone derivatives and their use as antitumor agents
US6780620B1 (en)	1998-12-23	2004-08-24	Bristol-Myers Squibb Company	Microbial transformation method for the preparation of an epothilone
US6596875B2 (en) *	2000-02-07	2003-07-22	James David White	Method for synthesizing epothilones and epothilone analogs
YU59001A (sh)	1999-02-18	2005-07-19	Schering Ag.	16-halogen-epotilon-derivati, postupak za njihovo dobijanje i njihova farmaceutska primena
CN1205208C (zh) *	1999-02-22	2005-06-08	生物技术研究股份有限公司	C－21修饰的环氧噻酮类化合物
US6211412B1 (en) *	1999-03-29	2001-04-03	The University Of Kansas	Synthesis of epothilones
PE20010116A1 (es)	1999-04-30	2001-02-15	Schering Ag	Derivados de 6-alquenil-, 6-alquinil- y 6-epoxi-epotilona, procedimientos para su preparacion
TWI310684B (en) *	2000-03-27	2009-06-11	Bristol Myers Squibb Co	Synergistic pharmaceutical kits for treating cancer
US6589968B2 (en) *	2001-02-13	2003-07-08	Kosan Biosciences, Inc.	Epothilone compounds and methods for making and using the same
US6489314B1 (en) *	2001-04-03	2002-12-03	Kosan Biosciences, Inc.	Epothilone derivatives and methods for making and using the same
US6906188B2 (en) *	2001-04-30	2005-06-14	State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University	Method for synthesizing epothilones and epothilone analogs
WO2003029195A1 (fr) *	2001-09-28	2003-04-10	Sumika Fine Chemicals Co., Ltd.	Intermediaires pour l'elaboration d'un derive de l'epothilone, et leur procede de production
US6884608B2 (en) *	2001-12-26	2005-04-26	Bristol-Myers Squibb Company	Compositions and methods for hydroxylating epothilones
TW200303202A (en)	2002-02-15	2003-09-01	Bristol Myers Squibb Co	Method of preparation of 21-amino epothilone derivatives
US6921769B2 (en) *	2002-08-23	2005-07-26	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
RU2368661C2 (ru)	2002-09-23	2009-09-27	Бристол-Маерс Сквибб Компани	Способы получения, выделения и очистки эпотилона b и рентгеноструктурные кристаллические структуры эпотилона в

1997
- 1997-11-18 AU AU54837/98A patent/AU753546B2/en not_active Expired
- 1997-11-18 DE DE59711647T patent/DE59711647D1/de not_active Expired - Lifetime
- 1997-11-18 PT PT97951233T patent/PT941227E/pt unknown
- 1997-11-18 PT PT03016552T patent/PT1367057E/pt unknown
- 1997-11-18 RU RU99113031/04A patent/RU2198173C2/ru active
- 1997-11-18 CN CNB971998140A patent/CN1196698C/zh not_active Expired - Lifetime
- 1997-11-18 BR BRPI9713363-9A patent/BR9713363B1/pt not_active IP Right Cessation
- 1997-11-18 CZ CZ0175099A patent/CZ296164B6/cs not_active IP Right Cessation
- 1997-11-18 NZ NZ335383A patent/NZ335383A/xx not_active IP Right Cessation
- 1997-11-18 ES ES97951233T patent/ES2221692T5/es not_active Expired - Lifetime
- 1997-11-18 PL PL333435A patent/PL193229B1/pl unknown
- 1997-11-18 EP EP97951233A patent/EP0941227B2/de not_active Expired - Lifetime
- 1997-11-18 DK DK97951233T patent/DK0941227T5/da active
- 1997-11-18 AT AT03016552T patent/ATE408612T1/de active
- 1997-11-18 CN CNB2005100062827A patent/CN100344627C/zh not_active Expired - Lifetime
- 1997-11-18 HU HU0000497A patent/HU229833B1/hu unknown
- 1997-11-18 JP JP52320898A patent/JP4274583B2/ja not_active Expired - Lifetime
- 1997-11-18 DK DK03016552T patent/DK1367057T3/da active
- 1997-11-18 AT AT97951233T patent/ATE267197T1/de active
- 1997-11-18 ES ES03016552T patent/ES2312695T3/es not_active Expired - Lifetime
- 1997-11-18 WO PCT/EP1997/006442 patent/WO1998022461A1/de active IP Right Grant
- 1997-11-18 CA CA2269118A patent/CA2269118C/en not_active Expired - Lifetime
- 1997-11-18 DE DE59712968T patent/DE59712968D1/de not_active Expired - Lifetime
- 1997-11-18 KR KR10-1999-7004302A patent/KR100538095B1/ko not_active IP Right Cessation
- 1997-11-18 EP EP03016552A patent/EP1367057B1/de not_active Expired - Lifetime
- 1997-11-18 IL IL12955897A patent/IL129558A/en not_active IP Right Cessation
- 1997-11-18 CZ CZ20041118A patent/CZ303422B6/cs not_active IP Right Cessation
1998
- 1998-01-21 TW TW086117334A patent/TW408119B/zh not_active IP Right Cessation
1999
- 1999-05-14 NO NO19992338A patent/NO319984B1/no not_active IP Right Cessation
2000
- 2000-02-29 HK HK00101272A patent/HK1022314A1/xx not_active IP Right Cessation
2004
- 2004-11-12 US US10/988,328 patent/US7067544B2/en not_active Expired - Fee Related
2005
- 2005-10-26 CY CY0500058A patent/CY2542B1/xx unknown
2006
- 2006-03-24 HK HK06103757A patent/HK1083832A1/xx not_active IP Right Cessation
- 2006-04-27 US US11/412,536 patent/US20060264482A1/en not_active Abandoned
2008
- 2008-04-28 US US12/110,781 patent/US20080293784A1/en not_active Abandoned
2009
- 2009-03-24 US US12/409,823 patent/US7846952B2/en not_active Expired - Fee Related
- 2009-05-01 US US12/434,078 patent/US7759375B2/en not_active Expired - Fee Related
2010
- 2010-12-06 US US12/961,447 patent/US8076490B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US7067544B2 (en)	2006-06-27
PT1367057E (pt)	2008-12-04
EP0941227A1 (de)	1999-09-15
NZ335383A (en)	2000-10-27
DK1367057T3 (da)	2009-01-19
US20080293784A1 (en)	2008-11-27
PT941227E (pt)	2004-08-31
IL129558A (en)	2001-10-31
CA2269118A1 (en)	1998-05-28
CN1680370A (zh)	2005-10-12
ES2221692T3 (es)	2005-01-01
EP1367057B1 (de)	2008-09-17
NO992338L (no)	1999-05-14
US7759375B2 (en)	2010-07-20
US20090247592A1 (en)	2009-10-01
BR9713363B1 (pt)	2011-02-08
CN1196698C (zh)	2005-04-13
HU229833B1 (en)	2014-09-29
NO319984B1 (no)	2005-10-10
CZ303422B6 (cs)	2012-09-05
JP2001504474A (ja)	2001-04-03
US8076490B2 (en)	2011-12-13
WO1998022461A1 (de)	1998-05-28
ATE408612T1 (de)	2008-10-15
DK0941227T4 (da)	2008-05-19
PL333435A1 (en)	1999-12-06
DE59711647D1 (de)	2004-06-24
EP0941227B2 (de)	2009-10-14
PL193229B1 (pl)	2007-01-31
KR20000053308A (ko)	2000-08-25
TW408119B (en)	2000-10-11
CZ175099A3 (cs)	1999-09-15
KR100538095B1 (ko)	2005-12-21
EP1367057A1 (de)	2003-12-03
NO992338D0 (no)	1999-05-14
AU5483798A (en)	1998-06-10
RU2198173C2 (ru)	2003-02-10
CZ296164B6 (cs)	2006-01-11
ES2221692T5 (es)	2009-12-14
CA2269118C (en)	2012-05-29
ES2221692T4 (es)	2005-10-01
AU753546B2 (en)	2002-10-24
EP0941227B9 (de)	2005-05-04
IL129558A0 (en)	2000-02-29
CY2542B1 (en)	2006-06-28
JP4274583B2 (ja)	2009-06-10
US20060264482A1 (en)	2006-11-23
US20110136185A1 (en)	2011-06-09
HUP0000497A2 (hu)	2000-06-28
ES2312695T3 (es)	2009-03-01
HUP0000497A3 (en)	2001-10-29
CN1237970A (zh)	1999-12-08
HK1022314A1 (en)	2000-08-04
US7846952B2 (en)	2010-12-07
DK0941227T3 (da)	2004-06-28
ATE267197T1 (de)	2004-06-15
DE59712968D1 (de)	2008-10-30
CN100344627C (zh)	2007-10-24
EP0941227B1 (de)	2004-05-19
HK1083832A1 (en)	2006-07-14
US20050090535A1 (en)	2005-04-28
BR9713363A (pt)	2000-01-25
US20090270466A1 (en)	2009-10-29

Publication	Publication Date	Title
DK0941227T3 (da)	2004-06-28	Epothilon D, dens fremstilling samt dens anvendelse som cytostatisk middel og som plantebeskyttelsesmiddel
ES2129457T3 (es)	1999-06-16	Proceso mejorado de sintesis de (5r)-1,1-dimetiletil 6-ciano-5-oxo-hexanoato.
NO953762D0 (no)	1995-09-22	Innrettet fiberarmert panel for deler av tre
DK0553213T3 (da)	1995-07-17	Fremgangsmåde til fremstilling af (4R-cis)-1,1-dimethylethyl-6-cyanomethyl-2,2-dimethyl-1,3-dioxan- 4-acetat
Nurhanan et al.	2005	Cytotoxic effects of the root extracts of Eurycoma longifolia Jack
GB2437442A (en)	2007-10-24	Improved process for purification of 6 acetyl 4,1',6' trichlorogalactosucrose and 4,1',6' trichlorogalactosucrose by chromatography on silanized silica gel
ERKEL et al.	1992	Antibiotics from basidiomycetes XLI clavicoronic acid, a novel inhibitor of reverse transcriptases from Clavicorona pyxidata (pers. ex fr.) doty
Guo et al.	2015	Two new diketopiperazines and a new glucosyl sesterterpene from Alternaria alternata, an endophytic fungi from Ceratostigma griffithii
AU2001258390A1 (en)	2001-11-26	Stain solution, which is devoid of phenol, for bacteria
ATE141039T1 (de)	1996-08-15	Antioxidantienherstellung
Arciniegas et al.	2008	Chemical constituents of Roldana lineolata
AU6202496A (en)	1997-02-13	Process for the isomerization of olefins
Soltis et al.	1982	Flavonoids of Penthorum sedoides
EA199800732A1 (ru)	1999-02-25	СПОСОБ ОЧИСТКИ 11b-21-ДИГИДРОКСИ-2 '-МЕТИЛ-5' b Н-ПРЕГНА-1,4-ДИЕНО - (17,16-ди)-ОКСАЗОЛ-3,20-ДИОНА
LV12433A (lv)	2000-02-20	Arilaminotriazolopiridinu iegusanas panemiens
ES1023954U (es)	1993-08-01	Cabezal para duchas perfeccionado.
WO2003045981A3 (en)	2003-12-24	Concentrating aqueous fractions of lisinopril by reverse osmosis
ES1030366U (es)	1995-08-01	Rebosadero perfeccionado, para bañeras y similares.
DK1353920T3 (da)	2004-12-06	Fremgangsmåde til fremstilling af i hovedsagen ren gamma-fase quinacridonpigment med stor partikelstörrelse
KR970001545A (ko)	1997-01-24	로바스타틴의 제조방법
GEP19960051B (en)	1996-07-26	Method for Isolation of Biologically Active Plant Peptides
UA33861A (uk)	2001-02-15	Конусний затвор
RU93057610A (ru)	1997-01-10	Способ обнаружения веществ с антигрибными свойствами методом биоавтографии
ES1039446U (es)	1998-12-16	Columna perfeccionada.